NEW YORK - A study recently reported in the New England Journal of Medicine found that combining a new drug with the standard ones could more effectively slow end-stage colorectal cancer, slightly prolonging victims' lives.
The drug irinotecan, also known as Camptosar, is already approved by the Food and Drug Administration (FDA) for treating patients with advanced, Stage IV colorectal cancer after standard drugs fail. Led by Dr. Saltz of Memorial Sloan-Kettering Cancer Center, a three-drug combination of irinotecan, fluorouracil, and leucovorin increased average survival to 15 months from 13 months, and the share of patients whose tumors temporarily shrank went to 50% from 28%.
In the current study, 226 patients received fluorouracil and leucovorin, while 231 patients got periodic shots of those two drugs plus irinotecan. For more information visit www.fda.gov.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.